Back to Results
First PageMeta Content
Business / Financial statements / Cash flow / Fundamental analysis / Earnings before interest / taxes / depreciation and amortization / Private equity / Income statement / Net profit / Free cash flow / Accountancy / Finance / Generally Accepted Accounting Principles


Press Release SALUGGIA, MARCH 8, 2013 THE BOARD OF DIRECTORS OF DIASORIN S.P.A. APPROVES THE FULL YEAR 2012 RESULTS AND THE COMPANY’S DRAFT
Add to Reading List

Document Date: 2013-03-08 08:02:47

Open Document

File Size: 477,24 KB

Share Result on Facebook

Company

CLIA / Group’s Parent Company / Murex / Trivitron Healthcare Group / FULL YEAR 2012 RESULTS AND THE COMPANY / DiaSorin Group / DIASORIN S.P.A. / NorDiag Group / /

Continent

Asia / North America / Europe / Africa / /

Country

Taiwan / Germany / Turkey / France / Russia / United States / Brazil / Italy / Australia / Portugal / China / Mexico / Spain / /

Currency

USD / EUR / /

/

Event

M&A / Dividend Issuance / /

IndustryTerm

healthcare spending / reference accounting principles / blood bank / extraction technology / molecular diagnostics products / important blood banks / manufacturing expenses / amplification technology / /

Person

Gustavo Denegri / Luigi De Angelis / Margherita Sacerdoti / /

/

Position

leader in product offerings / second producer / Riccardo Fava External Relations Director / Investor Relations Specialist / General / Head / Officer / /

Product

Vitamin D / /

Region

Latin America / South America / Asia Pacific / Central America / /

Technology

LAMP amplification technology / extraction technology / /

SocialTag